IRVING, Texas, March 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Carrington Laboratories, Inc. (CARN) announced that David Erinakes has joined the company as vice president, sales and marketing.

Mr. Erinakes brings broad experience in the medical device, capital equipment and pharmaceutical sales marketplaces. Most recently, he served as vice president of sales for VIASYS Inc.'s NeuroCare Group. Under his leadership at VIASYS, Mr. Erinakes established a sales force organizational structure for the company that drove a substantial increase in both productivity and efficiency as well as record sales across three product lines (Neurology, Vascular and Audio). He also served as a member of the NeuroCare Operating Committee.

Prior to VIASYS, Mr. Erinakes was vice president of sales at Cyberonics Inc., a $100-million Houston-based international company. While at Cyberonics he received numerous achievement awards for his sales initiatives, including the President's Club Award (three-time winner), the Chairman's Eagle Award (presented to the individual who most contributed to the company's success), and was named Director of the Year for the company.

Mr. Erinakes also served as sales manager for the Southeastern Specialty Area of Pfizer Pharmaceuticals, New York, NY where he was integral in launching several Pfizer products.

Mr. Erinakes received a BA in psychology from the University of Dallas and an MBA from the University of Oklahoma. He also served in the US Army and the Army Reserve, specializing in intelligence and special operations.

"Dave brings a wealth of solid sales and marketing experience to Carrington and a strong eye for developing new and expanded applications for platform products and technologies," notes Carlton E. Turner, PhD, Carrington's chief executive officer. "We look forward to his leadership in sales growth in our medical services division and guidance to our efforts to grow consumer and international sales."

About Carrington

Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical and consumer products company currently utilizing naturally-occurring polymeric carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products under the AloeCeuticals(R) brand and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. The Company's DelSite Biotechnologies subsidiary is developing its propriety GelSite(TM) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 126 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10Q filed November 12, 2004.